Piperacillin-lnduced Acute Interstitial Nephritis

Soto, Juan I.; Bosch, J. M.; Ortiz, Miguel; Moreno, Mar; González, Juan D.; Díaz, Juan Sánchez

doi:10.1159/000187461

Cited by 15 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results were consistent with the data in the current literature: 60 of the 68 analysed drugs were known to cause kidney damage (i.e. as described in the Summary of Product Characteristics or in the Micromedex drug information database) .…”

Section: Discussionsupporting

confidence: 92%

The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database

Pierson-Marchandise

Gras

Moragny

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database

Pierson-Marchandise

Gras

Moragny

et al. 2017

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Mechanistically, it is well established that VIKI is caused by 1) oxidative stress (28) and uromodulin interaction/cast formation (27) leading to acute tubular necrosis (ATN) (44, 45) and 2) rarely acute interstitial nephritis (AIN) (28). Piperacillin can rarely cause AIN (29). However, no clinical study has studied or demonstrated that synergistic toxicity occurs because of these mechanisms, only that SCr increases.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, SCr can be falsely elevated even when the kidney is not injured because of drug competition for renal tubular secretion (26). Unlike VAN, which causes AKI by inducing oxidative stress at the renal proximal tubule, resulting in uromodulin interaction/cast formation (27) and ATN (28), TZP very rarely causes AKI (28, 29). To date, only AIN has been cited with TZP in a few case reports.…”

Section: Introductionmentioning

confidence: 99%

Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model

Pais

Liu

Avedissian

et al. 2019

Preprint

View full text Add to dashboard Cite

word count: 294 34 2 | Page Abstract: 35Introduction: Vancomycin and piperacillin tazobactam (VAN+TZP) are two of the most 36 commonly utilized antibiotics in the hospital setting and are reported in clinical studies to 37 increase acute kidney injury (AKI). However, no clinical study has demonstrated that synergistic 38 toxicity occurs, only that serum creatinine (SCr) increases with VAN+TZP. The purpose of this 39 study was to assess biologic plausibility by quantifying kidney injury between VAN, TZP, and 40 VAN+TZP treatments using a translational rat model of AKI and rat kidney epithelial cell studies. 41 Methods: (i) Male Sprague-Dawley rats (n=32) received either saline, VAN 150 mg/kg/day 42 intravenously, TZP 1400 mg/kg/day via intraperitoneal injection, or VAN+TZP. Animals were 43 placed in metabolic cages pre-study and on drug dosing days 1-3. Urinary biomarkers and 44 histopathology were analyzed. (ii) Cellular injury of VAN+TZP was assessed in serum-deprived 45 rat kidney cells (NRK-52E) using an alamarBlue® viability assay. Cells were incubated with 46 antibiotics VAN, TZP, cefepime, and gentamicin alone or combined with the same drugs plus 47 VAN 1 mg/mL. 48Results: In the VAN-treated rats, urinary KIM-1 and clusterin were increased on days 1, 2, and 3 49 compared to controls (P<0.001). Elevations were seen only after 3 days of treatment with 50 VAN+TZP (P<0.001 KIM-1, P<0.05 clusterin). Histopathology was only elevated in the VAN 51 group when compared to TZP as a control (P=0.04). Results were consistent across biomarkers 52and histopathology suggesting that adding TZP did not worsen VAN induced AKI and may even 53 be protective. In NRK-52E cells, VAN alone caused moderate cell death with high doses (IC50 54 48.76 mg/mL). TZP alone did not cause cellular death under the same conditions. VAN+TZP 55 was not different from VAN alone in NRK-52E cells (P>0.2). 56Conclusions: VAN+TZP does not cause more kidney injury than VAN alone in a rat model of 57 VIKI or in rat kidney epithelial cells. 58 59 3 | Page

show abstract

“…Published reports evaluating PTZ nephrotoxic potential are sparse. PTZ has been implicated in AKI through acute interstitial nephritis (AIN) in at least eight case reports . The use of vancomycin and PTZ combination in adults, however, has recently been reported to significantly increase the risk of AKI relative to vancomycin monotherapy .…”

mentioning

confidence: 99%

“…PTZ has been implicated in AKI through acute interstitial nephritis (AIN) in at least eight case reports. [12][13][14][15][16][17][18][19] The use of vancomycin and PTZ combination in adults, however, has recently been reported to significantly increase the risk of AKI relative to vancomycin monotherapy. [20][21][22][23][24][25][26] The exact mechanism of action underlying the association between AKI and the vancomycin-PTZ combination remains to be fully understood.…”

mentioning

confidence: 99%

Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

Abouelkheir

Alsubaie

2018

Pediatrics International

View full text Add to dashboard Cite

show abstract

Piperacillin-lnduced Acute Interstitial Nephritis

Cited by 15 publications

References 8 publications

The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database

The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database

Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model

Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin–tazobactam

Contact Info

Product

Resources

About